Table 4. Univariate and multivariate analyses of the OS.
| Characteristics | OS | |||
|---|---|---|---|---|
| Univariate | Multivariate | |||
| HR (95% CI) | p-value* | HR (95% CI) | p-value† | |
| Age (≥ 50 vs. < 50 yr) | 0.580 (0.180–1.900) | 0.372 | - | - |
| Hypertension (yes vs. no) | 0.980 (0.750–2.130) | 0.129 | - | - |
| Hyperlipidemia (yes vs. no) | 0.920 (0.120–7.140) | 0.936 | - | - |
| BMI (≥ 23 vs. < 23 kg/m2) | 0.710 (0.230–2.180) | 0.553 | - | - |
| Tumor location (left vs. right) | 1.080 (0.360–3.210) | 0.893 | - | - |
| BCS (no vs. yes) | 3.320 (1.080–10.180) | 0.035 | 1.764 (0.544–5.715) | 0.344 |
| SLNB (no vs. yes) | 2.020 (0.550–7.390) | 0.286 | - | - |
| Pathologic subtype (others vs. IDC) | 2.230 (0.490–2.510) | 0.298 | - | - |
| T stage (≥ T2 vs. T1) | 10.220 (1.330–78.770) | 0.026 | 7.781 (0.998–60.690) | 0.050 |
| N stage (≥ N1 vs. N0) | 4.530 (0.590–35.010) | 0.148 | 4.363 (0.520–36.572) | 0.175 |
| Estrogen receptor (positive vs. negative) | 0.460 (0.150–1.410) | 0.128 | - | - |
| Progesterone receptor (positive vs. negative) | 0.680 (0.220–2.070) | 0.493 | - | - |
| HER-2 (positive vs. negative) | 0.770 (0.240–2.510) | 0.666 | - | - |
| Vascular invasion (present vs. absent) | 3.400 (0.440–26.240) | 0.241 | - | - |
| Lymphatic invasion (present vs. absent) | 0.640 (0.080–4.900) | 0.664 | - | - |
| p53 (positive vs. negative) | 1.240 (0.420–3.700) | 0.700 | - | - |
| Ki67 (positive vs. negative) | 1.180 (0.360–3.830) | 0.785 | - | - |
| Radiotherapy (yes vs. no) | 0.730 (0.200–2.670) | 0.638 | - | - |
| Hormone therapy (yes vs. no) | 0.510 (0.170–1.560) | 0.237 | 0.460 (0.150–1.407) | 0.173 |
| Target therapy (yes vs. no) | 0.840 (0.260–2.730) | 0.773 | - | - |
| Hyperglycemia (yes vs. no) | 2.510 (0.770–8.160) | 0.126 | 2.775 (0.828–9.308) | 0.098 |
OS = overall survival; HR = hazard ratio; CI = confidence interval; BMI = body mass index; BCS = breast conserving surgery; SLNB = sentinel lymph node biopsy; IDC = ninvasive ductal carcinoma; HER-2 = human epidermal growth factor receptor 2.
*Kaplan-Meier survival estimates compared by log-rank test; †Cox proportional hazards model.